Victory Capital Management Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Victory Capital Management Inc. raised its position in Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 142.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 214,794 shares of the medical research company’s stock after buying an additional 126,149 shares during the quarter. Victory Capital Management Inc. owned approximately 0.42% of Charles River Laboratories International worth $42,271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 5,935,727 shares of the medical research company’s stock valued at $1,685,568,000 after buying an additional 66,602 shares during the last quarter. Clearbridge Investments LLC increased its holdings in shares of Charles River Laboratories International by 7.3% in the second quarter. Clearbridge Investments LLC now owns 1,468,682 shares of the medical research company’s stock valued at $314,254,000 after purchasing an additional 99,739 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Charles River Laboratories International by 399.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,104,292 shares of the medical research company’s stock valued at $236,285,000 after purchasing an additional 883,029 shares during the period. Mackenzie Financial Corp increased its holdings in shares of Charles River Laboratories International by 15.3% in the second quarter. Mackenzie Financial Corp now owns 987,234 shares of the medical research company’s stock valued at $211,238,000 after purchasing an additional 131,020 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 51.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 976,347 shares of the medical research company’s stock valued at $192,144,000 after purchasing an additional 331,084 shares during the period. Hedge funds and other institutional investors own 97.80% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent research reports. Jefferies Financial Group lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, January 12th. JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. Robert W. Baird upped their price objective on Charles River Laboratories International from $275.00 to $285.00 and gave the stock an “outperform” rating in a report on Wednesday, January 11th. Morgan Stanley dropped their price objective on Charles River Laboratories International from $250.00 to $241.00 and set an “equal weight” rating on the stock in a report on Thursday, November 3rd. Finally, Credit Suisse Group dropped their price objective on Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $297.38.

Charles River Laboratories International Stock Up 4.1 %

Shares of NYSE:CRL opened at $243.17 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 1.12. Charles River Laboratories International, Inc. has a 52-week low of $181.36 and a 52-week high of $349.84. The stock’s fifty day simple moving average is $226.53 and its 200-day simple moving average is $218.49. The company has a market capitalization of $12.37 billion, a P/E ratio of 28.64, a P/E/G ratio of 1.46 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The medical research company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.12. Charles River Laboratories International had a return on equity of 20.93% and a net margin of 11.54%. The business had revenue of $989.16 million for the quarter, compared to the consensus estimate of $978.65 million. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Shannon M. Parisotto sold 2,279 shares of the stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total transaction of $569,522.10. Following the transaction, the executive vice president now directly owns 2,499 shares in the company, valued at $624,500.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Shannon M. Parisotto sold 2,279 shares of the stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total transaction of $569,522.10. Following the transaction, the executive vice president now directly owns 2,499 shares in the company, valued at $624,500.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael Gunnar Knell sold 855 shares of the stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $248.59, for a total value of $212,544.45. Following the transaction, the chief accounting officer now owns 6,438 shares in the company, valued at $1,600,422.42. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,077 shares of company stock worth $2,334,821. 1.10% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.